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Abstract
Background
Ultra deep sequencing is of increasing use not only in research but also in diagnostics. For
implementation of ultra deep sequencing assays in clinical laboratories for routine diagnos-
tics, intra- and inter-laboratory testing are of the utmost importance.
Methods
Amulticenter study was conducted to validate an updated assay design for 454 Life Sci-
ences’GS FLX Titanium system targeting protease/reverse transcriptase (RTP) and env
(V3) regions to identify HIV-1 drug-resistance mutations and determine co-receptor use
with high sensitivity. The study included 30 HIV-1 subtype B and 6 subtype non-B samples
with viral titers (VT) of 3,940–447,400 copies/mL, two dilution series (52,129–1,340 and
25,130–734 copies/mL), and triplicate samples. Amplicons spanning PR codons 10–99, RT
codons 1–251 and the entire V3 region were generated using barcoded primers. Analysis
was performed using the GS Amplicon Variant Analyzer and geno2pheno for tropism. For
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comparison, population sequencing was performed using the ViroSeq HIV-1 genotyping
system.
Results
The median sequencing depth across the 11 sites was 1,829 reads per position for RTP
(IQR 592–3,488) and 2,410 for V3 (IQR 786–3,695). 10 preselected drug resistant variants
were measured across sites and showed high inter-laboratory correlation across all sites
with data (P<0.001). The triplicate samples of a plasmid mixture confirmed the high inter-
laboratory consistency (mean% ± stdev: 4.6 ±0.5, 4.8 ±0.4, 4.9 ±0.3) and revealed good
intra-laboratory consistency (mean% range ± stdev range: 4.2–5.2 ± 0.04–0.65). In the two
dilutions series, no variants >20% were missed, variants 2–10% were detected at most
sites (even at low VT), and variants 1–2% were detected by some sites. All mutations
detected by population sequencing were also detected by UDS.
Conclusions
This assay design results in an accurate and reproducible approach to analyze HIV-1
mutant spectra, even at variant frequencies well below those routinely detectable by popu-
lation sequencing.
Introduction
HIV-1 drug resistance testing is currently recommended and widely implemented as the stan-
dard of care prior to starting antiretroviral therapy (ART) [1]. The standard method used
worldwide for drug resistance testing is based on population sequencing, which does not allow
for the detection or reporting of minority HIV-1 drug-resistance mutations [2]. Several meth-
ods are available for detection of minority mutations [3]. Tests based on allele specific PCR
(AS-PCR) can be used for high sensitivity detection of minority variants; however, this technol-
ogy can only detect one mutation per assay and becomes very labor intensive for analysis of
multiple resistant variants [4, 5]. Next Generation Sequencing assays, having the capability to
analyze multiple drug resistance mutations in a single assay, are being used with increasing fre-
quency [6]. Ultra deep sequencing (UDS) has been retrospectively assessed in clinical trials
such as the MOTIVATE and A4001029 studies where viral tropism was determined phenotyp-
ically prior to maraviroc administration [7]. The presence of2% non-R5 HIV by UDS was
found to be a good predictor of virologic response to maraviroc [7].
UDS has been indicated in previous studies to be an important tool for drug resistance
detection due to its ability to detect and quantify minority drug resistance mutations. A system-
atic review and pooled analysis showed the risk of virological failure to be significantly
increased in ART-naïve patients receiving an NNRTI-based first line regimen who harbor pre-
existing minority NNRTI-resistant HIV-1 variants [8] recently confirmed by a multi-cohort
European case-control study [9]. The latter and all of the studies analyzed in this pooled analy-
sis; however, were retrospective in nature. Prospective studies have not yet been completed to
unequivocally show the clinical relevance of minority HIV-1 drug-resistance mutations. Fur-
thermore, clinical cut-offs for the significance of such minority HIV-1 drug-resistance muta-
tions have yet to be defined. More sensitive assays and studies are required to answer these
questions. Here, we describe an assay with the potential to help answer these questions.
Intra- and Inter-Laboratory Validation of Ultra Deep Sequencing
PLOS ONE | DOI:10.1371/journal.pone.0146687 January 12, 2016 2 / 17
Applied Science. MSB owns Roche stocks. KJM has
received travel grants and honoraria from Gilead
Sciences, Roche Diagnostics, Tibotec, Bristol-Myers
Squibb, and Abbott; the University of Zurich has
received research grants from Gilead, Roche, and
Merck Sharp & Dohme for studies that KJM serves
as principal investigator, and advisory board
honoraria from Gilead Sciences. MPD has received
travel grants from Abbott and MSD Sharp & Dohme,
has received a research grant from MSD Sharp &
Dohme (IISP ID#: 34988), and has been an adviser
for Merck Sharp & Dohme, Gilead Sciences, and
Janssen & Cila. JA is employed by Janssen
Infectious Diseases – Diagnostics bvba, a Johnson &
Johnson company, and owns stocks of this company.
All other authors declare no competing interest. This
does not alter the authors’ adherence to PLOS ONE
policies on sharing data and materials.
We previously described a multicenter study demonstrating high inter-laboratory correla-
tion of UDS-detected minority HIV-1 drug-resistance mutations exclusively in HIV-1 subtype
B samples. This initial study was completed using the GS FLX sequencing platform [10] and
focused on the detection of minority HIV-1 drug-resistance mutations in the RTP region of
HIV-1 subtype B viruses. The follow-up study described here employed an updated primer
design consisting of 8 amplicons between 400 and 600 bp (including sequencing adaptors and
multiplex identifier (MID); also commonly referred to as a barcode) that target multiple clades
of HIV-1 samples. The new assay design takes advantage of longer read lengths and also
includes the V3 loop of the env gene to provide viral co-receptor use information (Fig A in S1
File).
Validation based on comparison to state of the art genotyping is a pre-requisite for adoption
of ultra deep sequencing in routine care settings. We investigated the inter- and intra-labora-
tory performance of a prototype HIV-1 primer set and sequencing protocol for ultra-deep pyr-
osequencing. In addition, we sought to demonstrate concordance with state of the art
genotyping as well as the detection of minority HIV-1 drug-resistance mutations in samples
from multiple HIV-1 clades.
Materials and Methods
Ethics statement
Human plasma used for this study was derived from anonymous blood donations obtained
from healthy blood donors provided by the Blood Donation Service. Written informed consent
or an ethics statement for the use of plasma from anonymous blood donations are not required
for research purposes.
Study design
HIV-1 containing samples were provided to 10 study sites in Europe and one study site in
South Africa. Site numbering began with the number 20 to disambiguate the new data files
from those generated in the previous study. The samples were comprised of 30 HIV-1 subtype
B and 6 subtype non-B samples (A2, AE, A/G, B/G, C, and G) with viral titers of 3,940–447,400
copies/mL, two dilution series (52,129–1,340 and 25,130–734 copies/mL, respectively), tripli-
cate samples and two plasmid controls (Table A in S1 File). All samples were sent blinded to
the sites. Also provided to each site were detailed laboratory protocols, four 96-well thermocy-
cler plates with ready to use cDNA primers as well a set of four 96-well thermocycler plates
that contained pre-loaded barcoded PCR primers for the generation of eight overlapping
amplicons. For traceability through the workflow, the barcode on the PCR primers in the first
column of each plate was unique to that plate. For the concordance analysis, population
sequencing of all samples was performed with the ViroSeq HIV-1 genotyping system by Dr.
Däumer’s clinical laboratory.
Primer design
The overlapping amplicons span PR codons 10–99, RT codons 1–251 and the entire V3 region.
The amplicons were designed to provide dual coverage for Stanford Database (version 6.0.9)
Drug Resistance PR and RT mutations with a score5 (any drug) and tropism determinants
in V3 (Fig A and Table A in S1 File). All primers were designed using the principles previously
described, with the exception of allowing for 98% conservations instead of 99% as described in
the referenced paper [11]. The longer read length chemistry employed in this study reduced
Intra- and Inter-Laboratory Validation of Ultra Deep Sequencing
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the required number of overlapping RTP amplicons from six to four and also allowed for place-
ment of primers in sufficiently conserved areas outside the V3 region.
Sample characteristics
The RTP samples used in this study were cultured recombinant virus diluted in plasma from
HIV-1 negative individuals. The cloned inserts included the coding regions for the complete
protease and the 5’ 302 amino acids (aa) of the reverse transcriptase (nucleotide positions
2,002 to 3,457 based on the reference sequence HIV-1HXB2, GenBank accession number
K03455). The V3 samples were cultured samples from patient isolates, diluted in HIV-1 nega-
tive plasma. Two control samples were generated for inter- and intra-laboratory comparison
purposes (control sample A) and for amplification control (control sample B). Control sample
A is a mixture of two plasmid samples obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: pM46I/L63P/V82T/I84V and pL10R/M46I/
L63P/V82T/I84V from Dr. Emilio Emini [12]. These two plasmids were mixed at a 20:1 ratio
to create a sample with the L10R mutation at approximately 5%. Control sample B is a prepara-
tion of plasmid pM46I/L63P/V82T/I84V.
HIV-1 RNA extraction, cDNA synthesis, amplification and pooling
1 ml of each sample was ultracentrifuged for 1.5 hrs at 4°C. 800 μl of the supernatant was
removed and discarded, leaving ~200 μL of viral pellet and plasma. HIV-1 RNA was extracted
using the QIAampMinElute Virus Spin kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. MS2 carrier RNA (Roche, Mannheim, Germany) was then added to
each eluate to a final concentration of 10 ng/μL. 13 μL of the RNA eluate was reverse tran-
scribed using Transcriptor Reverse Transcriptase (Roche) with each of the “4R”, “5R” and/or
“V3R” primers (provided in ready to use 96-well plates), resulting in three first strand cDNA-
fragments covering the protease, reverse transcriptase and env V3 coding regions of HIV-1.
The cDNA was treated with RNAseH (Roche) and 3 μL cDNA product used for each PCR
reaction.
Amplicons were generated from the cDNA and the two plasmid control samples (A and B)
by 40 cycles of PCR with FastStart HiFi Polymerase (Roche) as depicted in Fig A in S1 File
using PCR conditions previously described [10] in a total of four 96-well thermocycler plates.
Primer sequences are given in Table B in S1 File. Amplicons were then purified with AMPure
XP beads (Agencourt, Beckman Coulter Inc.) and quantified using the Quant-iT PicoGreen
dsDNA kit (Invitrogen, Darmstadt, Germany). Amplicons with concentrations<5 ng/μL were
further analyzed on a 2100 Bioanalyzer (Agilent Technologies, Böblingen, Germany). PCR
products with a molar ratio of primer-dimer to amplicon above 1:3 were excluded from sample
pooling. The remaining amplicons were pooled equimolarly by sample MID (6 RTP and 2 V3
amplicons for each MID), with any missing amplicon being compensated for by increasing the
amount of an overlapping amplicon, where possible. The samples were then pooled by plate to
make 4 final pools, 1 pool per plate corresponding to 1 pool per region of a 454 sequencing
pico titer plate (PTP) fitted with a 4-lane gasket. In total, 36 samples (18 for sequencing of the
RTP region and 18 for the env V3 region) were amplified in PCR plates 1 and 2, corresponding
to regions 1 and 2 of the sequencing run. 3 additional samples were amplified in triplicate on
plate 3 (9 samples total, sequencing both the RTP- and env V3 regions), corresponding to
region 3 of the sequencing run. Amplicons for the two sample dilution series were generated
on plate 4 (10 samples total, sequencing both the RTP- and env V3 regions), corresponding to
region 4. Control sample A was amplified in each of the first 3 plates and included in the pools
for sequencing. Control sample B was used as an amplification control on each of the four
Intra- and Inter-Laboratory Validation of Ultra Deep Sequencing
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plates to ensure proper execution of the PCR step as was a negative water control to ensure no
contamination of the PCR; neither of these controls was included in the pools for sequencing.
Ultra deep sequencing
Each of the 4 amplicon pools was separately subjected to clonal emulsion PCR amplification
on beads using reagents that enabled sequencing in both the forward and reverse directions
(Lib-A kit, 454 Life Sciences—A Roche Company, Branford). DNA-containing beads were
counted on a Multisizer3 instrument (Beckman Coulter Inc.) and prepared for sequencing.
Approximately 790,000 beads from each of the four pools were loaded in the four regions of a
PTP fitted with a 4-lane gasket. Sequencing was performed on a GS FLX Titanium System (454
Life Sciences -A Roche Company, Branford). Resulting sequence reads were aligned to HIV-
1HXB2 by the GS Amplicon Variant Analyzer (AVA) v2.3 software included with the 454 Life
Sciences instrument. The AVA software demultiplexed barcoded reads and aligned them to the
HIV-1HXB2 reference while simultaneously eliminating primer-derived sequences. The soft-
ware then reported the prevalence of both sequence conservation and mutations relative to
HIV-1HXB2. Since AVA detects variants in nucleotide space, configuration files were provided
to each site that defined amino acid mutations based on triplets of nucleotides. Sff files are
deposited in the European Nucleotide Archive (accession number PRJEB12165)
Data analyses
Data was analyzed for intra- and inter-laboratory concordance using the R statistical package
[13] or GraphPad Prism software (GraphPad Software, San Diego, CA). The correlation of var-
iant prevalence for sample replicates within sites and common samples across sites was also
computed. In addition, the minimum, maximum and median variant levels, as reported by
each site, were calculated to assess concordance with population sequencing results for all sam-
ples. For minority variant calling, 1% was chosen as cut off based on previous reports showing
combined PCR and pyrosequencing error rates of 0.1–0.3% using HIV-derived clonal
sequences [14–16].
Tropism analysis was performed with the geno2pheno co-receptor algorithm for each V3
sample at a false positive rate setting of 3.75% using AVA preprocessed files. Finally, standard
population sequencing was performed on each sample using the ViroSeq HIV-1 genotyping
system (Abbott Laboratories, Abbott Park, Illinois).
Results
Overall performance
Ten out of eleven sites delivered a complete data set. Sequencing information was obtained for
2,986 of 3,520 (85%) expected amplicons. One site was unable to deliver information for the
second of their four plates (Table 1) and other sites encountered sporadic amplification fail-
ures. Table C in S1 File describes the details for each amplicon drop-out. The higher rate of
drop-outs in plate 4 are due to the lower viral titers associated with the dilution series samples.
Fig B I in S1 File shows the uniform distribution of the total number of high quality (HQ)
reads (those reads that passed the amplicon data processing pipeline) per sequencing region
for each site. Furthermore, almost all of the HQ reads could be aligned to HIV-1HXB2 with the
exception of those from site 27 (region 2) and sites 26 and 28 which delivered a reduced total
number of HQ reads.
Analysis of the distribution of the 8 amplicons revealed that there was a reduced number of
HQ reads (across sites) for amplicons RTP4 and RTP5 for all sites when compared to the
Intra- and Inter-Laboratory Validation of Ultra Deep Sequencing
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number of reads for amplicons RTP1-3, 6, V3A and V3B. Fig B II in S1 File depicts the HQ
read distribution data per site for each amplicon using region 3 of the 4-region PTP as a repre-
sentative example. Across all plates and sites, the median sequencing depth was 1,829 reads per
position for RTP (IQR = 592–3,488) and 2,410 reads per position for V3 (IQR = 786–3,695).
Inter-laboratory concordance
To determine inter-laboratory variability of the current workflow for end users, each site was
given a questionnaire to identify and report variant percentages using the AVA software. Ten
preselected drug resistance mutations were chosen for this analysis, two were expected nega-
tives (V179D, F227L), three were<5% prevalence (V75A, V82I, G73S) and the remaining five
were>10% prevalence (Table 1). All readings reported in this table required a minimum of 15
reads in addition to successful amplicon generation as indicated by the amplification control
on the relevant plate. A read coverage of<15 was defined as sequencing failure. Of those
amplicons reported with sufficient read coverage, all but one was accurately detected and
reported. The single highly inconstant variant was the I54V protease mutation on plate #2 of
site 27. The site reported technical errors with this particular plate. Overall, the 10 preselected
drug resistant variants, including those with non-B subtypes, showed high inter-laboratory cor-
relation across all sites (Table 1).
Detection of a minority variant in a plasmid mix
To determine the consistency of variant detection, not only between laboratories but also
across plate amplification, an engineered plasmid mixture was sequenced in triplicate at each
site (Table 2). The replicate plasmid mixtures were distributed over 3 of the 4 PCR plates and
contained a single low level mutation in the protease region, L10R. The mean reported frequen-
cies for this variant across all 11 sites for plates 1, 2 and 3 were 4.7, 4.8 and 4.8% with standard
deviations of 0.5, 0.6 and 0.3%, respectively. The replicate plates within each site had means
ranging from 4.3 to 5.2% with standard deviations of 0.3 and 0.4%, respectively (Table 2).
Table 1. Detection across sites of 10 preselected variants. The table lists the percentage of reads carrying the codon variant.
Drug resistance mutation Sample HIV-1 subtype Study sites
20 21 23 24 25 26 27 28 29 30 31 Median IQR
NNRTI-G190A 1 G 28.5 23.4 26.5 27.7 27.2 35.3 32.6 18.2 33.0 27.8 27.8 27.8 3.7
NNRTI-F227L 3 B 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
NRTI-K219R 4 B 62.6 58.3 65.6 60.6 58.6 58.2 62.1 67.0 57.2 62.8 65.0 62.1 5.5
NRTI-V75A 5 A2 2.8 1.6 1.1 1.1 0.7 1.7 0.7 2.5 0.5 1.2 1.3 1.2 0.8
PI-p-V82I 19 B 1.7 1.4 n.a.a 1.8 1.1 0.6 —b 1.4 0.9 1.4 1.3 1.4 0.3
PI-I54V 20 B 54.8 99.3 98.6 98.7 98.4 99.7 0.0 95.2 51.0 49.6 99.2 98.4 46.1
NRTI-L74I 21 B 8.7 12.2 15.7 11.4 9.1 11.0 — 10.4 9.7 11.1 11.0 11.0 1.5
NNRTI-V179D 24 AG 0.0 0.0 0.0 0.0 0.0 0.0 — 0.0 0.0 0.0 0.0 0.0 0.0
PI-G73S 26 B 2.8 3.7 4.5 4.8 4.7 4.9 — 4.1 3.4 1.5 3.6 3.9 1.2
NRTI-V118I 27 C 30.0 35.4 32.7 34.8 36.6 56.3 — 39.0 15.1 28.2 27.8 33.8 7.7
a not applicable, i.e., fewer than 15 reads in each direction
b no data returned.
doi:10.1371/journal.pone.0146687.t001
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Concordance with population sequencing
The ViroSeq assay was performed on the sample set by a single laboratory to determine con-
cordance with UDS. 99%-100% of drug resistance mutations detected by the population
sequencing-based assay were also found by UDS by all sites (Table 3). Three categories of
mutations were analyzed: i) major, defined as having a Stanford drug resistance database score
>5, ii) polymorphic, defined as having a Stanford drug resistance database score<5 and iii)
bulk, defined as any other difference from HIV-1HXB2 at the amino acid level. The single dis-
crepancy between UDS and population sequencing for the polymorphic mutation may be due
to low sequencing coverage.
Of clear clinical interest, we found that several population sequencing-called mutations
were incorrect due to the inability of population sequencing to phase adjacent nucleotides. Fig
C in S1 File is a representative screenshot from the AVA software showing the composition of
the UDS sequence reads at codon 215 in the reverse transcriptase. Population sequencing
called several possible mutations that could be present at this location although the mutations
could not be resolved due to the lack of phase information. This phenomenon occurs since
population sequencing only provides information about the composition at each nucleotide
location but not about how the nucleotides are connected in each variant. As shown in Fig C in
S1 File, UDS resolved the actual variant codon compositions, making it clear that only TAT
(Tyr) and ACT (Thr) were present. Population sequencing is not able to disambiguate between
Table 2. Consistency of variant detection for an engineered plasmidmix. A plasmid mix containing a
variant present at approximately 5% was sequenced in triplicate at each site. The frequency of the minority
variant is given in percent. The replicates were distributed over 3 of the 4 PCR plates.
Plates
Site 1 2 2 Median IQR
20 4.4 4.0 4.6 4.4 0.3
21 5.2 4.7 5.2 5.2 0.3
23 5.4 5.1 4.5 5.1 0.5
24 4.4 4.3 4.9 4.4 0.3
25 4.3 5.1 5.3 5.1 0.5
26 4.2 5.0 4.6 4.6 0.4
27 4.9 5.9 4.7 4.9 0.6
28 4.5 3.7 4.3 4.3 0.4
29 4.1 5.2 4.8 4.8 0.6
30 5.6 4.7 5.4 5.4 0.4
31 5.0 5.1 5.0 5.0 0.0
Median 4.5 5.0 4.8
IQR 0.8 0.6 0.5
doi:10.1371/journal.pone.0146687.t002
Table 3. Concordance between amino acid mutations detected by population and ultra-deep pyrosequencing. Included in the analysis were all non-
redundant RTP samples (1–9, 19–27, 37 replicate #2, 38 replicate #2, and 39 replicate #2).
Mutation type Population sequencing Also detected by 454_UDS (%)
Major mutations (Stanford score >5) 72 72 (100)
Polymorphisms (Stanford score <5) 113 112 (99)
Bulk, differences from HIV-1HXB2 391 391 (100)
doi:10.1371/journal.pone.0146687.t003
Intra- and Inter-Laboratory Validation of Ultra Deep Sequencing
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the 4 possible combinations TAT (Tyr), AAT (Asn), TCT (Ser), and ACT (Thr) and thus the
associated software called all possible known resistance-linked variants at this position. These
obvious incorrect combinations in the population sequencing data were excluded prior to the
concordance analysis shown in Table 3.
Additional mutations found by UDS but not population sequencing are listed in Table 4.
Most of these were minority drug resistance mutations, i.e., found in less than 20% in a given
sample. However, several of these mutations were detected at levels>20% by UDS, likely
reflecting the inherent variability in population sequencing sensitivity. Most of these mutations
were detected and reported at similar frequencies by all sites with sufficient coverage for the
respective amplicons (Table 4).
Reproducibility and repeatability
To determine inter- and intra-laboratory reproducibility, a set of triplicate samples was distrib-
uted to each of the sites. The triplicate samples 37, 38 and 39 had previously been sequenced
Table 4. Drug resistancemutations found only by UDS. For each detected drug resistance mutation, the table indicates the sample, the number of sites
detecting the mutation at a frequency above 0.5%, the number of sites with coverage of at least 15 reads and the median, mean, minimum andmaximum vari-
ant frequencies. Details on reports of each site are given in Table D in S1 File.
Drug resistance mutation Sample Sites 0.5%a Sites with coverageb Median (%) Mean (%) Minimum (%) Maximum (%)
NNRTI-F227L 1 11 11 1.64 1.82 0.83 5.99
NNRTI-K103N 2 11 11 10.71 9.98 5.07 15.56
NNRTI-K103R 2 9 11 1.23 1.71 0 6.19
PI-V82A 3 10 11 4.87 4.55 0 6.37
NRTI-Y115F 4 11 11 4.20 3.83 1.14 5.52
NRTI-K70E 5 11 11 6.88 6.85 5.21 9.62
NRTI-V75A 5 11 11 1.19 1.39 0.55 2.84
NNRTI-G190A 7 11 11 3.44 3.33 1.52 5.88
NNRTI-Y188C 7 11 11 19.09 19.47 16.29 21.86
NRTI-M184V 7 11 11 7.54 7.58 3.22 10.27
PI-V82A 7 10 11 2.09 2.06 0.31 3.18
NNRTI-E138G 8 5 10 0.66 1.18 0 4.77
PI-M46V 8 11 11 2.70 2.79 1.65 4.25
NNRTI-V179D 9 11 11 1.43 1.71 1.03 2.74
NRTI-T215Y 19 10 10 8.32 8.03 5.55 10.38
NRTI-T69A 19 10 10 4.65 5.01 2.97 9.83
NRTI-T69N 19 7 10 1.02 1.71 0.16 5.08
NRTI-M184I 20 10 10 6.21 6.91 5.12 10.15
NRTI-L74I 21 10 10 10.99 11.03 8.77 15.74
NNRTI-K103R 23 9 9 19.79 20.82 17.01 26.84
PI-I47V 23 9 9 4.30 4.96 2.44 9.87
NNRTI-E138G 24 9 10 6.69 7.50 0 17.54
NNRTI-K103R 25 9 10 17.97 16.74 0 26.59
NRTI-K219E 25 9 10 6.38 5.93 0 9.52
NRTI-T69N 25 9 10 22.41 22.38 0 42.57
NNRTI-F227L 26 10 10 12.18 12.14 9.31 14.17
PI-G73S 26 10 10 3.89 3.81 1.51 4.93
a 0.5% was chosen to cover the expected errors on measurements of a 1% variant
b every site was included reporting at least 15 reads at the certain position. Fewer than 15 reads were deﬁned as unsuccessful ampliﬁcation.
doi:10.1371/journal.pone.0146687.t004
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and analyzed in the initial multicenter collaborative study [10]. These samples had viral titers
of 230,700, 447,400 and 80,000 copies/mL, respectively. Variant percentages measured in the
triplicate samples are shown for each mutation in Fig 1. Triplicate readings for mutations
detected in these samples are closely clustered within each site, indicating high intra-site repro-
ducibility (repeatability). The highest degree of variability recorded for several variants was
seen in site 28. This increased variation between triplicates may have been related to the very
low number of HQ aligned reads in region 3 for this site (Fig B I in S1 File) which was less than
Fig 1. Triplicate sample analysis. A set of three samples was measured in triplicate at each of the 11 sites. Variant percentages measured in the triplicate
samples are shown for each mutation.
doi:10.1371/journal.pone.0146687.g001
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half of all other sites. In addition, this data set also indicates high inter-site reproducibility as
all mutations were detected across sites with an average standard deviation of 1.0.
Variant detection in dilution series
To examine the limitations of sequencing samples with reduced viral titers, two samples with
starting viral titers of 52,119 and 25,130 copies/mL were serially diluted in human plasma four
times each to reach a lower viral titer of 1,340 and 734 copies/ml, respectively (Table A in S1
File). To ensure accuracy of the viral titers in the dilution series, the titer was re-determined on
aliquots from each dilution. Subsequently, 1 ml of each dilution was extracted, had amplicons
generated and was sequenced alongside the other HIV-1 samples. Fig 2 displays the amplicon
sequencing coverage for the second dilution series sample. Drug resistance mutations in fre-
quencies of>20% were detected by 90–100% of the sites, independent of the viral titer. Lower
viral titers led to a decrease in detection of minority drug resistance mutations, especially when
present at 1–2%. Of note, even these very low frequency mutations were still detected (on aver-
age) at approximately one quarter of the sites at a viral titer of 1,340 copies/mL (sample 44; Fig
2A).
Co-receptor usage prediction
Co-receptor usage calls for all V3 samples are shown in Table 5. The geno2pheno[454] algo-
rithm (Max-Planck-Institute for Informatics, Saarbrücken, Germany) was used to analyze the
UDS reads with a false positive ratio (FPR) setting of 3.75%. 14 of the samples sequenced by
UDS for the V3 region were also analyzed by population sequencing. For those 14 samples, 13
(93%) co-receptor usage calls were concordant between both systems. The single discrepancy
between the population sequencing and UDS based co-receptor usage predictions (sample 16)
was due to a discordant result from a single site. This site reported 86.4% for V3A and 75.7%
for V3B whereas all other sites reported a detection level of 0.0% X4 for both amplicons V3A
and V3B and may be due to a sample swap.
Discussion
The data presented here demonstrate that ultra deep sequencing can provide highly consistent
results together with excellent cross-site correlation. For all drug resistance mutations identi-
fied by the Stanford Drug Resistance Database in the sequenced region, we demonstrate near
perfect concordance with population sequencing results. In addition, 41 mutations were found
by UDS in the reverse transcriptase and protease regions at frequencies below 20%. These low
frequency mutations could not be detected by population sequencing due to its inherently
lower sensitivity [2]. Several studies have previously reported high concordance of UDS and
standard population sequencing for mutations present at levels greater than 20–25% (reviewed
in [6, 17]). One such study reported similar reproducibility of the UDS results with a correla-
tion value of r2 = 0.969 [18].
Additionally, some variants called by population sequencing were incorrect due to the
inability of population sequencing to phase individual nucleotides. In the example shown in
Fig C in S1 File, population sequencing analysis indicated four possible mutations at codon
215, i.e., T215 (ACT), T215Y (TAT), T215S (TCT), and T215N (AAT). In this particular case,
the Serine and Asparagine codons were listed as a combinatorial possibility by the ViroSeq
data analysis software, but UDS shows that both are not present among the actual quasispecies.
Since T215Y is detected with both methods, it makes no clinical difference in this case, but it is
easy to see how in certain instances this could cause interpretation of resistance where none is
present, leading to unnecessary avoidance of a potentially useful drug regimen. Looking at the
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Fig 2. Drug resistance mutation detection in limiting dilution series. Two HIV-1 subtype B samples were used for the dilution series (A, samples 40–44;
B, samples 45–49). The four groups shown in the histogram are based on the median frequency of each drug resistance mutation in its respective undiluted
sample: >20% (white bars), 10–20% (bright grey bars), 2–10% (dark grey bars), and 1–2% (black bars). The means and standard deviations are given of the
percentage of sites reporting drug-resistance mutations in these categories. The number of mutations in each category is represented by n.
doi:10.1371/journal.pone.0146687.g002
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technical performance of the assay, it was clear that certain amplicons performed more
robustly than others, both in PCR and sequencing. In general, shorter amplicons can be
expected to amplify with higher efficiency than longer ones [19]. This phenomenon negatively
affected the number of HQ reads for amplicons RTP4 and RTP5, the two longest amplicons in
the set, across all sites. It was also noted that the sequencing run at site 29 yielded a dispropor-
tionally large number of HQ reads. This difference was found to be due to a custom change in
their software pipeline settings allowing more HQ reads to be reported; however, this can lead
to reduced accuracy and is generally not recommended. The AVA software automatically dis-
carded the majority of the additional low accuracy reads and the variant percentages reported
from site 29 were similar to those reported by other sites. Conversely, sites 26 and 28 had aver-
age read counts but produced a significantly reduced number of aligned reads. This was likely
due to the presence of increased amounts of primer dimers that were introduced, along with
the amplicons of interest, into the emPCR step prior to the sequencing run. The presence of
primer dimers in emPCR is deleterious to the amplification of target amplicons as these shorter
Table 5. Co-receptor usage predictions. Calculations for UDS were performed using geno2pheno with a false positive rate setting of 3.75% and reported
as means with standard deviations for each sample across all sites.
V3 Sample X4 prediction based on UDS (%) Prediction based on population sequencing [FPR]a
Amplicon V3-A Amplicon V3-B
Mean StdDev Mean StdDev
10 0.1 0.2 0.6 1.8 R5 [42.3]
11 0.0 0.0 0.0 0.0 R5 [12.5]
12b n.a.c n.a. n.a. n.a.
13 0.0 0.0 0.1 0.4
14 99.8 0.4 99.7 0.3
15 0.0 0.0 0.0 0.0 R5 [93.5]
16d 6.9 22.8 8.6 27.3 R5 [35.3]
17 98.6 4.8 99.2 2.8
18 97.6 2.0 94.8 3.8 X4 [0.2]
28 82.8 12.3 84.8 12.5 X4 [0.2]
29 86.4 7.5 92.6 4.4 X4 [2.6]
30 99.7 0.3 99.2 2.1 X4 [0.1]
31 0.2 0.5 0.2 0.6 R5 [35.3]
32 0.0 0.1 0.1 0.2 R5 [76.0]
33 0.2 0.3 0.3 0.4 R5 [13.8]
34 0.1 0.3 0.1 0.2 R5 [38.8]
35 0.0 0.0 1.7 5.0 R5 [46.0]
36 0.0 0.0 0.0 0.1 R5 [38.5]
37–2 99.6 1.1 99.9 0.1
38–2 99.6 1.1 100.0 0.1
39–2 100.0 0.0 100.0 0.0
a Prediction of HIV-1 tropism by the geno2pheno [co-receptor] algorithm was done using a FPR of 10% according to the European guidelines on the
clinical management of HIV-1 tropism testing [34]
b geno2pheno algorithm3 only accepted <1% of the reads for sample 12
c not applicable
d The high stdev for sample 16 resulted from a discrepancy at a single site. Without that site the %X4 would have been 0% for both V3A and V3B,
agreeing with an R5 population sequencing- based prediction.
doi:10.1371/journal.pone.0146687.t005
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fragments are preferentially amplified on the beads [20]. This phenomenon results in a
decreased number of amplified target amplicons available for sequencing.
Assay performance at low viral titers was investigated with two dilution series. Data gath-
ered across all sites demonstrated that, even at low titers, mutations present at>20% of the
viral population were generally detected. Minority HIV-1 drug resistance mutations in the
range of 2–10% were detected at the majority of sites, and minority HIV-1 drug resistance
mutations in the range of 1–2% were still detected by some sites. It should be noted that the fre-
quency categories in Fig 2 are based on the variant percentage measured in the undiluted sam-
ple which most closely reflects the true representation of the viral species present in the sample.
When the viral titer decreases, stochastic sampling and decreased PCR efficiency will cause dis-
tortion of the ratio between the different viral species after amplification, and thus the frequen-
cies of individual variants [21].
Sequencing of the V3 region yielded reads spanning the entire V3 loop, which means that
each variant can be analyzed without making any inferences about phase. The geno2pheno co-
receptor usage prediction software can then simply assign each read to the appropriate pre-
dicted tropism group (ie., X4 or R5) and make an overall call based on a relevant false positive
rate setting [7, 22]. As noted in the introduction, this approach has been tested in retrospective
clinical trials. Theoretically, the increased sensitivity as well as the full phase information
should allow for more accurate X4 detection than population based sequencing. Such detailed
information is also of great interest for studies of HIV variant dynamics [23, 24]. In this study,
the only available comparison data was generated by population sequencing, and we demon-
strate good concordance between the two technologies. The single discrepancy noted in
Table 5 between the population sequencing and the 454 UDS X4/R5 prediction is for sample
16 where the high standard deviation was caused by an outlying result from a single site. If the
data from this site is excluded, the %X4 reporting is 0% for both V3A and V3B amplicons in
concordance with the population sequencing based prediction.
There is an increasing awareness of errors that are artificially introduced during RT-PCR
and subsequent pyrosequencing and can be falsely interpreted as real mutations [6]. Errors
introduced during the cDNA synthesis can currently not be distinguished from real mutations
and occur sporadically and randomly [25]. They would need to be the subject of resampling
during the following PCR to account for at least 1% of the viral population; the cut-off chosen
for our assay. Substitutions occurring during PCR could be addressed using, for instance, ran-
dom sequence primer identifiers (ID) [26]. Again, our approach to set the cut-off for minority
HIV-1 drug-resistance mutations to 1% minimizes false positive calling of most of PCR-intro-
duced mutations except those which occur in the first PCR cycles. Another source of potential
error is artificial recombination, the rate of which is highly correlated with the number of DNA
templates used in the PCR reaction [14, 27, 28]. The current assay does not contain a step to
normalize the transferred cDNA molecules and may therefore not be suitable to link certain
drug resistance mutations at low levels, especially in very high viral load samples.
Finally, we must consider errors introduced during the process of pyrosequencing. The 1%
cut-off for minority HIV-1 drug-resistance mutations is approximately a magnitude higher
than the reported substitution rates introduced by pyrosequencing [29, 30]. In addition, muta-
tions must be detected in both forward and reverse reads at the approximate same frequency to
be deemed real. Insertions and deletions (indels) occur predominantly in homopolymer
regions [29, 30] and artifactual variant calling can be mitigated by using appropriate platform
specific analysis software such as AVA to appropriately align reads and by manually inspecting
the alignments in regions with homopolymer runs. Given the very high reproducibility of vari-
ants across sites in this study, we feel confident that we have adequately addressed these sources
of error for potential use in a clinical setting. In addition, we have greatly reduced the
Intra- and Inter-Laboratory Validation of Ultra Deep Sequencing
PLOS ONE | DOI:10.1371/journal.pone.0146687 January 12, 2016 13 / 17
possibilities that exist for introducing human error during manual handling in the laboratory.
Compared to the initial multicenter study [10], where several severe errors occurred, the new
concept of providing dried down primers in plates proved very successful. In addition to “lock-
ing down” the positions of cDNA and PCR primers, we introduced a tracking MID on each
plate to ensure that pools from each plate ended up in the intended region on the sequencing
run. Additional improvements in the making are color coding and orientation marks on indi-
vidual plates. As long as materials for individual sequencing runs are kept separate, the main
source of manual error remains potential sample swaps, a problem that all clinical laboratories
face and have learned to minimize.
454 ultra deep sequencing will only be supported through 2016. Nevertheless, this assay
design, either directly or via primer recombination, could be transferred to other next genera-
tion sequencing platforms allowing long amplicon sequencing provided by, for instance, Illu-
mina [31, 32], Pacific Biosciences [32], Ion Torrent [32], or Oxford Nanopore Technologies.
Regardless of the technology used, our inter- and intra-laboratory testing in a multicenter col-
laborative study shows that this kind of validation is of the utmost importance when UDS
assays are to be considered for implementation in a routine diagnostic setting.
Conclusion
The field of virology continues to study minority HIV-1 drug resistance mutations and their
relevance in the drug resistance field, although the clinical impact is still controversially dis-
cussed [8, 9, 33] and there remain challenges such as the search for clinically relevant cut offs.
Nevertheless, as next-generation sequencing technologies become more affordable and accessi-
ble, they will more regularly play a key role in these studies due to their accuracy, reproducibil-
ity and throughput. Thus, intra- and inter-laboratory testing is important for implementation
of ultra deep sequencing assays in clinical laboratories for routine diagnostics. The updated
assay design described herein for resistance testing and co-receptor usage prediction by ultra
deep sequencing allows for an accurate and highly reproducible approach to analysis of the
HIV-1 mutant spectra, even at frequencies well below those detected by standard population
sequencing.
Supporting Information
S1 File. Fig A: Overview of amplicon locations. Reference amplicon sizes (incl. adapters and
MIDs) are as follows: (A) RTP1 = 419 bp, RTP2 = 510 bp, RTP3 = 400 bp, RTP4 = 599 bp,
RTP5 = 558 bp, RTP6 = 434 bp; (B) V3A = 465 bp, V3B = 423 bp. Fig B: HQ reads and
aligned reads distribution. I) The number of HQ reads, aligned and not aligned, per sequenc-
ing region of the PTP for each site II) The percent composition of total sequencing reads (in
brackets below the site name) obtained from each amplicon at each site using region 3 as a rep-
resentative example. Fig C: AVA software screen shot of the global alignment of sample 3
from site 31 of low frequency mutation RT215. Population sequencing indicated the possibil-
ity of amino acids Threonine (ACT), Tyrosine (TAT), Serine (TCT), and Asparagine (AAT) at
codon 215 in the reverse transcriptase. These could not be further resolved, as the codon nucle-
otides cannot be phased. The 454 pyrosequencing reads resolved the actual variant codon com-
positions: 52.0% TAT (Tyr), and 46.9% ACT (Thr) (only mutations present at>1% included).
The variants TCT (Ser) and AAT (Asn) could not be detected. Table A: Overview of sample
viral titers and clades used for this study. 30 HIV-1 subtype B and 6 subtype non-B samples
were used for RTP and V3 sequencing, three HIV-1 subtype B samples were run in triplicate
(samples 37, 38 and 39) and two HIV-1 subtype B samples were used for the dilution series
(samples 40–44 and 45–49). The RTP, dilution samples and triplicate samples are cultured
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recombinant virus, whereas V3 samples are cultured samples from patient isolates. The viral
titer for each is shown. Table B: Primers. Table C: Details of amplicon drop out across sites
per amplicon. Lack of amplicon production was reported by each site as any amplicon measur-
ing less than 1 ng/μL or that was comprised of primer dimer alone. All amplicon concentration
measurements were taken following PCR and purification. Table D: Drug resistance muta-
tions found only by UDS. Details on reports of each site. The summary of the data are given
in table 4. Hits, number of reads reporting the variant; denom, number of total reads at this
position.
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